Divarasib outperforms first-generation KRAS-G12C inhibitors in NSCLC

Diana Romero
Nature Reviews Clinical Oncology · Springer Nature · 2026-11-09 · DOI: 10.1038/s41571-026-01233-z

Abstract

Nature Reviews Clinical Oncology, Published online: 09 November 2026; doi:10.1038/s41571-026-01233-z Divarasib outperforms first-generation KRAS-G12C inhibitors in NSCLC

Read at publisher →

Similar articles